Ming-Wei Wu, DO
Surgery · Pomona, CANPI 1578500336
Payments from drug & device makers
Across 160 payments — averaging $231.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Triad Life Sciences Inc.$32K
- Kerecis Limited$2K
- KCI USA, Inc.$976
- Smith+Nephew$807
- Melinta Therapeutics, LLC$484
- Organogenesis Inc.$206
- plus $879 from 16 others
What the payments were for
- Consulting fees$1110%
- Travel & lodging$1,2173%
- Food & beverage$3,64310%
- Other$32,00087%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Triad Life Sciences Inc. | 1 | $32,000 |
| Kerecis Limited | 6 | $1,619 |
| KCI USA, Inc. | 10 | $976 |
| Smith+Nephew | 85 | $807 |
| Melinta Therapeutics, LLC | 14 | $484 |
| Organogenesis Inc. | 7 | $206 |
| Paratek Pharmaceuticals, Inc. | 9 | $141 |
| Next Science LLC | 2 | $111 |
| Novo Nordisk | 5 | $108 |
| Solventum Corporation | 4 | $102 |
| Ascensia Diabetes Care US Inc. | 1 | $75 |
| Reddress USA, Inc. | 1 | $70 |
| Amgen(2 entities) | 3 | $67 |
| Mannkind Corporation | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Misonix Inc | 2 | $30 |
| Hartmann USA, Inc. | 1 | $24 |
| AbbVie | 1 | $24 |
| Bayer | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Reprise Biomedical, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$32,000
- Kerecis Omega3 Marigen$2,904
- Kerecis Omega3 SurgiClose$2,535
- Kerecis Omega3 GraftGuide$1,497
- SNAP$520
- Kerecis Omega3 Wound$183
- Kerecis Omega3 Surgibind$183
- VAC VERAFLO$145
- Rezzayo$126
- Kimyrsa$125
- KERRACONTACT AG (US)$121
- KERRAMAX CARE$121
- KERRAFOAM GENTLE BORDER$121
- V.A.C. VERAFLO$115
How this compares
$36,971 in reported general payments places this provider in the 90th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nystatin | 34 | $733 |
| Silver Sulfadiazine | 22 | $430 |
| Triamcinolone Acetonide | 14 | $291 |
| Mupirocin | 17 | $162 |
| Hydrocortisone | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other surgery in Pomona
- Timothy ChuterSan Francisco$8.9M
- Peter StockSan Francisco$6.5M
- Santiago HorganSan Diego$2.8M
- Kenneth DeckLaguna Hills$2.4M
- Daniel RiskinSan Jose$2.2M
- Michael DemeureNewport Beach$1.7M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.